Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET

Company Participants

Brennan Doyle - Head of Investor Relations
Jeff Dayno - President & Chief Executive Officer
Jeffrey Dierks - Chief Commercial Officer
Kumar Budur - Chief Medical Officer
Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer

Conference Call Participants

Francois Brisebois - Oppenheimer
Charles Duncan - Cantor Fitzgerald
Ami Fadia - Needham
David Amsellem - Piper Sandler
Graig Suvannavejh - Mizuho
David Wong - Citigroup
Corinne Jenkins - Goldman Sachs
Pavan Patel - Bank of America

Operator

Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences' Second Quarter 2024 Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I will now turn the call over to Brennan Doyle, Head of Investor Relations. Please go ahead.

Brennan Doyle

Thank you, operator. Good morning, everyone and thank you for joining us today, as we review Harmony Biosciences' second quarter 2024 financial results and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.

Our speakers on today's call are Dr. Jeff Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical Officer; and Scientific Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer.

As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.

I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff?

Jeff Dayno

Thank you, Brian, and thanks everyone for joining our conference call today. Q2 was another very productive quarter for the team in Harmony, delivering another quarter of strong revenue growth for WAKIX and continued advancement in our late-stage clinical development programs, highlighted by the significant progress made on our next-generation pitolisant high dose were Pitolisant HD development program, formerly referred to as NG2.